Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma.
The role of serum macrophage inflammatory protein-1 alpha (MIP-1alpha) in bone disease and survival was evaluated in 85 newly diagnosed multiple myeloma (MM) patients. MIP-1alpha was elevated in MM patients and correlated with the extent of bone disease, bone resorption markers and levels of soluble receptor activator of nuclear factor-kappaB (RANK) ligand. MIP-1alpha was also associated with survival; the 3-year probability of survival was 85% and 44% for MIP-1alpha levels below and above 48 pg/ml respectively (P = 0.021). This suggests that MIP-1alpha contributes to the pathogenesis of bone disease in MM and possibly in tumour growth, as reflected by its impact on survival.
D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001862:Bone Resorption; D002352:Carrier Proteins / Q000097:blood; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D005260:Female; D006801:Humans; D019402:Macrophage Inflammatory Proteins / Q000097:blood*; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood* / Q000401:mortality / Q000473:pathology; D011336:Probability; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D033581:Stem Cell Transplantation; D015996:Survival Rate
D014408:Biomarkers, Tumor; D002352:Carrier Proteins; D054405:Chemokine CCL3; D054407:Chemokine CCL4; D019402:Macrophage Inflammatory Proteins; D008562:Membrane Glycoproteins; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; C505686:TNFRSF11A protein, human; C505688:TNFSF11 protein, human